Decision-Making in Diagnosis and Management of Extraintestinal Manifestations of Inflammatory Bowel Disease

Crossmark: check for updates

Authors

  • Nicholas V. Costrini Borland Groover Clinic, PA, 4800 Belfort Road, Jacksonville, FL 32256, USA

DOI:

https://doi.org/10.17140/GOJ-5-133

Keywords:

Ulcerative colitis, Crohn’s disease, Erythema nodosum, Pyoderma gangrenosum, Primary sclerosing cholangitis, Spondyloarthritis, Uveitis, Paradoxical dermatitis

Abstract

In the absence of certainty regarding the causes of both inflammatory bowel disease (IBD) and its extraintestinal manifestations (EIMs), there is necessarily ambiguity in both academic and clinical arenas concerning the diagnosis, classifications, and treatments of EIMs. While the “true” EIMs are considered extensions of the IBD gut pathogenesis with an immunologically mediated inflammatory consequence, other EIMs are considered to be complications of IBD itself or its treatment. A third group of IBD EIMs includes those disorders which seem to occur more often in IBD but for which an etiologic or pathophysiologic connection to IBD is highly theoretical. Patients with IBD and EIMs tend to have more severe, long-duration disease, and a reduced quality of life. EIMs presentation may or may not parallel IBD gut inflammatory activity. The clinical decision-making processes necessary for successfully managing simultaneously the gut component of IBD and its EIMs are presented. Based upon clinical experience and review of leading publications, the consensus of best practices, differential diagnoses for EIMs, and current management programs are presented with enumeration of specific decisions and considerations required for successful management of EIMs. EIMs of inflammatory bowel disease reflect the immunopathologic common ground and hence the systemic nature of the IBD. A defined decision-making process is offered which includes consultations and attention to the differential diagnosis to avoid not uncommon mistakes in diagnosis. Management of all EIMs requires assessment of both the clinical and pathologic status of the gut component of IBD combined with judicious selection of general and /or immunosuppression therapy for the EIMs.

References

Guan Q. A comprehensive review and update on the patho-genesis of inflammatory bowel disease. J Immunol Res. 2019; 2019: 7247238. doi: 10.1155/2019/7247238

Strober W, Fuss IJ. Pro-inflammatory cytokines in the pathogen-esis of IBD. Gastroenterology. 2011; 140: 1756-1767. doi: 10.1053/j. gastro.2011.02.016

Chang, JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020; 383: 2652-2664. doi: 10.1056/NEJMra 2002697

Guillo L, D’Amico, Serrero M, Angioi K, Loeuille D, Costanzo A, et al. Assessment of extraintestinal manifestations in inflamma-tory bowel diseases: A systematic review and a proposed guide for 11 Costrini NV clinical trials. United European Gastroenterol J. 2020; 8(9): 1013-1030. doi: 10.1177/2050640620950093

Juillerat P, Manz M, Sauter B, Zeitz J, Vavricka SR, IBDnet S, et al. Therapies in inflammatory bowel disease patients with extrain-testinal manifestations. Digestion. 2020; 101 (suppl 1): 83-97. doi: 10.1159/000502816

Harbord M, Annese V, Vavricka SR, Allez M, Acosta MB, Bo-berg KM, et al. The first European evidenced-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn’s and Colitis. 2016; 10(3): 239-254. doi: 10.1093/ecco-jcc/ jjv213

Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, et al. The pathogenesis of extraintestinal manifestations: Im-plications for IBD research, diagnosis, and therapy. J Crohn’s and Colitis. 2019; 13(5): 541-554. doi: 10.1093/ecco-jcc/jjy191

Garber A, Regueiro M. Extraintestinal manifestations of inflam-matory bowel disease: Epidemiology, and management. Curr Gas-tro Rep. 2019; 21: 31-44. doi: 10.1007/s11894-019-0698-1

Huang BL, Chandra S, Shin DQ. Skin manifestations of inflam-matory bowel disease. Front. Physiol. 2012; 3: 1-13. doi: 10.3389/ fphy.2012.00013

Bunted K, Beaker T. The TH 17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflam-matory diseases. Int J Mol Sci. 2019; 20: 3394-3418. doi: 10.3390/ ijms20143394

Vavricka SR, Brun L, Ballabeni P, Pittet V, Vavricka BMP, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011; 106: 110-119. doi: 10.1038/ajg.2010.343

Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, et al. Occurrence of skin manifestations in patients of the Swiss inflammatory bowel disease cohort study. PLoS One. 2019; 14(1): e0210436. doi: 10.1371/journal.pone.0210436

Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. evolution on prednisolone. Group d’Etude thera-peutique des affections inflammatoires digestives. Gastroenterology. 1990; 98(4): 811-818. doi: 10.1016/0016-5085(90)90002-i

Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn’s disease activity: Comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010; 16(12): 2131-2136. doi: 10.1002/ibd.21300

Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment of extraintestinal mani-festations of inflammatory bowel disease in the Swiss cohort Review | Volume 5 | Number 1| study. Inflamm Bowel Dis. 2017; 23(7): 1174-1181. doi: 10.1097/ MIB.0000000000001109

Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Vavricka MP, Navarini AA, et al. Chronological order of appearance of extraint-estinal manifestations relative to time of diagnosis of IBD diagno-sis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis. 2015; 21(8): 1794-1800. doi: 10.1097/MIB.0000000000000429

Weizman AV, Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, et al. Pyoderma gangrenosum among patients with in-flammatory bowel disease: A descriptive cohort study. J Cutan Med Surg. 2015; 19(2): 125-131. doi: 10.2310/7750.2014.14053

Aberumand B, Howard J, Howard J. Metastatic Crohn’s disease: An approach to an uncommon but important cutaneous disorder. Biomed Res Int. 2017; 2017: 8192150. doi: 10.1155/2017/8192150

Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019; 10: 282-295. doi: 10.3389/fphar.2019.00282

Rudwalet M, van der Heijde D, Landewe R, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011; 70(1): 25-31. doi: 10.1136/ard.2010.133645

Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15(12): 1915-1924. doi: 10.1002/ibd.20942

Biedermann L, Renz L, Fournier N, Rossel J-B, Butter M, Blue-mel S, et al. Uveitis manifestations in patients of the Swiss inflam-matory bowel disease cohort study. Ther Adv Gastroenterol. 2019; 12: 1756284819865142. doi: 10.1177/1756284819865142

Salmon JF, Wright JP, Murray ADN. Ocular manifestations in Crohn’s disease. Ophthalmology. 1991; 98(4): 480-484. doi: 10.1016/ SO161-6420(91)32268-1

Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10(2): 135- 139. doi: 10.1097/00054725-200403000-00012

Navaneethan U, Shen B. Hepatopancreaticobiliary manifes-tations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(9): 1598-1619. doi: 10.1002/ ibd.21219

Weismuller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Pon-sioen CY, et al. Patient age, sex, and inflammatory bowel disease phenotype associated with the course of primary sclerosing chol-Submit your article to this journal | https://openventio.org/submit-manuscript/ Review | Volume 5 | Number 1| Costrini NV angitis. Gastroenterology. 2017; 152(8): 1975-1984.e8. doi: 10.1053/j. gastro.2017.02.038

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary scleros-ing cholangitis. Hepatology. 2010; 51(2): 660-678. doi: 10.1002/ hep.23294

Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008; 134(4): 975-980. doi: 10.1053/j.gastro.2008.01.042

Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary scle-rosing cholangitis. Nat Rev Gastroenterol Hepatol. 2009; 6(5): 287- 295. doi: 10.1038/nrgastro.2009.26

Moran GW, Dubeau M-F, Kaplan GG, Yang H, Eksteen B, Ghosh S, et al. Clinical predictors of thiopurine-related adverse events in Crohn’s disease. World J Gastroenterol. 2015; 21(25): 7795- 7804. doi: 10.3748/wjg.v21.i25.7795

Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoof-nagle JH, et al. Liver injury from cyclosporine A. Dig Dis Sci. 1990; 35(6): 693-697. doi: 10.1007/BF01540169

Bath RK, Brar NK, Forouhar FA, Wu GY. A review of metho-trexate-associated hepatotoxicity. J Dig Dis. 2014; 15(10): 517-524. doi: 10.1111/1751-2980.12184

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Casteele NV, Breynaert C, et al. Characteristics of skin lesions as-sociated with ant-tumor necrosis factor therapy in patients with inflammatory bowel disease: A cohort study. Ann Intern Med. 2016; 164(1): 10-22. doi: 10.7326/M15-0729

Melo F, Magina S. Clinical management of anti-tnf-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: A systematic review. Int J Dermatol. 2018; 57(12): 1521-1532. doi: 10.1111/ijd.14072

Thibault H, Thibault P, Guingona C, Guillaume N, Wacre-nier A, Sabbagh C, et al. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. Eur J Gastroenterol Hepatol. 2016; 28(8): 876-1881. doi: 10.1097/ MEG.0000000000000643

Ezzedine K, Visseaux L, Cadiott G, Brixi H, Bernard P, Reguiai Z, et al. Ustekinumab for skin reactions associated with anti-tumor necrosis-α agents in patients with inflammatory bowel diseases: A single-center retrospective study. J Dermatol. 2019; 46(4): 322-327. doi: 10.1111/1346-8138.148

Published

2021-06-19

How to Cite

Nicholas V. Costrini. (2021). Decision-Making in Diagnosis and Management of Extraintestinal Manifestations of Inflammatory Bowel Disease. Gastro, 5(1), 4–12. https://doi.org/10.17140/GOJ-5-133

Similar Articles

<< < 1 2 3 4 > >> 

You may also start an advanced similarity search for this article.